Navigation Links
Early In Vivo Visualization of Retinoblastoma Tumors in Histologic Detail

Indianapolis, In. (PRWEB) August 28, 2013

Researchers at the Eugene and Marilyn Glick Eye Institute at the Indiana University School of Medicine have been successful in visualizing retinoblastoma tumors in Tag-RB mice as early as 8 weeks of age using OCT technology. This is one week earlier than reported in the literature.1,2. By 10 weeks of age, retinoblastoma tumors in this transgenic mouse model were clearly delineated within the inner nuclear layer. The Phoenix Research Laboratories Image-Guided OCT facilitates in-vivo imaging of the tumors in histologic detail.

“The strength of in-vivo OCT imaging in mice lies not only in detailing the foci of the lesions within the retinal layers, but in the ability to monitor tumor growth longitudinally with documentation of the invasion or disruption of the inner and outer retina.” notes Tim Corson, PhD, Assistant Professor at the Glick Eye Institute, Indianapolis.

Retinoblastoma is the most common eye malignancy in children, usually affecting those younger than age 5. Early detection is the key to successful treatment of this blinding and potentially lethal cancer. Mouse models of retinoblastoma have provided insights into the development and treatment of tumors in the retina, as well the genetic pattern of inheritance of other cancers.

The Phoenix Image-Guided OCT delivers longitudinal resolution under 2 microns and enables precise OCT scan placement by providing a guide beam in the bright field image. Even small lesions not visible in the bright field image can be detected by OCT, easily scanned and their location referenced.

“We are excited and pleased by the contribution the Phoenix Image-Guided OCT System is making in groundbreaking research such as this retinoblastoma study,” said Bert Massie, PhD, Chairman and CEO of Phoenix Research Labs. “The power of in vivo OCT imaging is fueling earlier detection discoveries while contributing to the understanding of tumorigenesis, morphology and treatment efficacies. We are honored to be playing a role in such impactful scientific advancements.”

About Phoenix Research Labs
Phoenix Research Labs is an animal eye research company focused on developing innovative technologies to advance the study of eye diseases. The Phoenix product line includes the Micron IV Retinal Imaging Microscope, Image-Guided OCT System, Ganzfeld ERG System, Image-Guided Focal ERG System, Image-Guided Laser System and Anterior Segment Image System. With systems located in the US, Europe, Asia and Latin America, Phoenix Research Labs has a global presence in the world ophthalmology research effort. Incorporated in 2008 by Dr. Bert Massie, the company is located in Pleasanton, CA. For more information visit

1.    Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1808-14. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. Ruggeri M, Wehbe H, Jiao S, Gregori G, Jockovich ME, Hackam A, Duan Y, Puliafito CA.
2.    Opt Express. 2009 Mar 2;17(5):4074-83. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, Murray TG, Puliafito CA.

Media Contacts:

Vicki Hermansen, Director, Marketing & Communications
Eugene and Marilyn Glick Eye Institute
IU School of Medicine Department of Ophthalmology

Melody Bertolucci, Director of Marketing
Phoenix Research Labs

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
2. JCI early table of contents for Aug. 15, 2013
3. JCI early table of contents for Aug. 8, 2013
4. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
5. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
6. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
7. Adult cells transformed into early-stage nerve cells, bypassing the pluripotent stem cell stage
8. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
9. Finally, the need of nearly every woman wanting to look more beautiful is fulfilled with Crisalix, the first online direct-to-consumer 3D imaging using standard pictures
10. Bed Bugs Get Family Throwing Nearly All Their Possessions, My Cleaning Offers Help With Complimentary Samples of Non-Pesticide Bed Bug Bully
11. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
Post Your Comments:
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):